Leaflet VAQTA 50U/ml 50 U / ml injection suspension


Indicated for: prevention of hepatitis A

Substance: inactivated hepatitis A vaccine (vaccine)

ATC: J07BC02 (Antiinfectives for systemic use | Viral vaccines | Hepatitis vaccines)

The inactivated hepatitis A vaccine is used to prevent infection with the hepatitis A virus (HAV), which can cause acute hepatitis, an inflammatory liver disease. The vaccine contains inactivated hepatitis A viruses, which stimulate the immune system to produce specific antibodies against HAV.

The vaccine is administered intramuscularly, usually in two doses, 6-12 months apart. It is recommended for individuals traveling to endemic areas, children, food industry workers, and others at increased risk of infection.

Common side effects include pain at the injection site, mild fever, fatigue, and nausea. In rare cases, severe allergic reactions may occur.

The inactivated hepatitis A vaccine is an important preventive measure for reducing the risk of HAV infection and its associated complications, contributing to public health protection.

General data about VAQTA 50U/ml 50 U / ml

  • Substance: inactivated hepatitis A vaccine
  • Date of last drug list: 01-07-2013
  • Commercial code: W51268003
  • Concentration: 50 U / ml
  • Pharmaceutical form: injection suspension
  • Quantity: 1
  • Product type: generic
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Concentrations available for inactivated hepatitis A vaccine

  • 1440 U.El./ml
  • 160 U ANTIGENICE
  • 25 U/0.5ml
  • 50 U/ml
  • 720 U. Elisa